Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Capital Expenditures (2016 - 2026)

Champions Oncology (CSBR) has 16 years of Capital Expenditures data on record, last reported at -$23000.0 in Q4 2025.

  • For Q4 2025, Capital Expenditures changed N/A year-over-year to -$23000.0; the TTM value through Oct 2025 reached $412000.0, up 155.15%, while the annual FY2025 figure was $389000.0, N/A changed from the prior year.
  • Capital Expenditures reached -$23000.0 in Q4 2025 per CSBR's latest filing, down from $46000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $2.2 million in Q1 2021 and bottomed at -$839000.0 in Q2 2024.
  • Average Capital Expenditures over 5 years is $483833.3, with a median of $536000.0 recorded in 2021.
  • Peak YoY movement for Capital Expenditures: surged 1178.95% in 2021, then plummeted 210.39% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $566000.0 in 2021, then increased by 6.71% to $604000.0 in 2022, then plummeted by 86.92% to $79000.0 in 2023, then tumbled by 1162.03% to -$839000.0 in 2024, then surged by 97.26% to -$23000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were -$23000.0 in Q4 2025, $46000.0 in Q3 2025, and -$39000.0 in Q2 2025.